The House Budget Committee wants to know whether the Congressional Budget Office (CBO) is continually updating its analysis of how the Inflation Reduction Act’s drug price controls will affect pharmaceutical innovation, noting new data have emerged since CBO initially estimated the law will lead to 13 fewer drugs coming to market over the next 30 years. Committee Chair Jodey Arrington (R-TX), the committee’s Health Care Task Force Chair Michael Burgess (R-TX) and other members of the GOP-led health task force...